Literature DB >> 33269910

Could Artesunate Have a Positive Effect on the Neurological Complications Related to Infection When It Is Used in the Treatment of COVID-19?

Tuğçenur Uzun1, Orçun Toptaş2, Şule Aydın Türkoğlu3.   

Abstract

Artesunate is a safe noncytotoxic drug with low side effects which is used in the treatment of chloroquine-resistant malaria. In addition to being an antimalarial drug, artesunate also has immunomodulatory, anticarcinogenic, and antiviral activity. There are in vivo and in vitro studies reporting that artesunate may have a positive effect on the treatment of COVID-19. Artesunate may be effective based on its effect on the anti-inflammatory activity, chloroquine-like endocytosis inhibition mechanism, and nuclear factor kappa B (NF-κB) signal pathway. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may cause neurological complications in addition to targeting the respiratory system. In this study, we have discussed the possible neuroprotective action mechanisms of artesunate. We think that systemic and intranasal topical artesunate administration may have a positive effect on neurological complications resulting from COVID-19.

Entities:  

Keywords:  COVID-19; Guillain-Barré; NF-κB; artesunate; intranasal; neurological; thrombocytosis

Year:  2020        PMID: 33269910     DOI: 10.1021/acschemneuro.0c00601

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  2 in total

Review 1.  Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug.

Authors:  Fatih M Uckun; Saran Saund; Hitesh Windlass; Vuong Trieu
Journal:  Front Pharmacol       Date:  2021-03-19       Impact factor: 5.810

2.  A case of successive development of possible acute necrotizing encephalopathy after COVID-19 pneumonia.

Authors:  Pasin Hemachudha; Thanakit Pongpitakmetha; Wanakorn Rattanawong; Poosanu Thanapornsungsuth; Yutthana Joyjinda; Saowalak Bunprakob; Chanida Ruchisrisarod; Thiravat Hemachudha
Journal:  SAGE Open Med Case Rep       Date:  2022-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.